UNIVERSITY OF SYDNEY

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Established: 1850-01-01

Employees: -

Market Cap: -

Website: https://www.sydney.edu.au/

Clinical Trials

MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy

Not yet recruiting

Conditions: Glioblastoma Multiforme

First Posted Date: 2022-08-15

Last Posted Date: 2024-06-06

Lead Sponsor: University of Sydney

Target Recruit Count: 20

Registration Number: NCT05500612

Locations: 🇦🇺
North Shore Private Hospital, St Leonards, New South Wales, Australia
🇦🇺
Royal North Shore Hospital, St Leonards, New South Wales, Australia

A Randomised Controlled Trial of N-acetylcysteine for the Management of Alcohol Use Disorder

Phase 4

Recruiting

Conditions: Alcohol Use Disorder (AUD)

Interventions: Drug: N-acetyl cysteine
Drug: Placebo

First Posted Date: 2022-06-07

Last Posted Date: 2023-03-16

Lead Sponsor: University of Sydney

Target Recruit Count: 280

Registration Number: NCT05408247

Locations: 🇦🇺
Turning Point, Richmond, Victoria, Australia
🇦🇺
Cornwall Street Medical Centre (UQ Health Care), Annerley, Queensland, Australia
🇦🇺
Drug Health Services, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

Collection of Head Images During Radiotherapy

Active, not recruiting

Conditions: Head and Neck Neoplasms
Radiation Therapy Complication

First Posted Date: 2022-02-01

Last Posted Date: 2024-06-07

Lead Sponsor: University of Sydney

Target Recruit Count: 32

Registration Number: NCT05218824

Locations: 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Recruiting

Conditions: Liver Cancer
Prostatic Cancer
Brain Cancer
Kidney Cancer
Head and Neck Cancer
Spinal Neoplasm
Arrhythmias, Cardiac
Breast Cancer
Pancreatic Cancer

First Posted Date: 2022-01-11

Last Posted Date: 2024-07-26

Lead Sponsor: University of Sydney

Target Recruit Count: 300

Registration Number: NCT05184790

Locations: 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺
Royal North Shore Hospital, Saint Leonards, New South Wales, Australia
🇦🇺
Alfred Health, Melbourne, Victoria, Australia

and more 1 locations

Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy

Recruiting

Conditions: Liver Neoplasm

First Posted Date: 2021-12-23

Last Posted Date: 2024-07-30

Lead Sponsor: University of Sydney

Target Recruit Count: 50

Registration Number: NCT05169177

Locations: 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺
Westmead Hospital, Westmead, New South Wales, Australia
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

and more 2 locations

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Phase 2

Terminated

Conditions: COVID-19
SARS-CoV2 Infection

Interventions: Drug: Candesartan Placebo
Drug: Candesartan Cilexetil
Drug: Repagermanium Placebo
Drug: Repagermanium

First Posted Date: 2021-11-16

Last Posted Date: 2023-09-15

Lead Sponsor: University of Sydney

Target Recruit Count: 49

Registration Number: NCT05122182

Locations: 🇮🇳
DM Wayanad Institute of Medical Sciences, Meppadi, India
🇮🇳
Sterling Hospital, Nigdi, India
🇮🇳
Jivanrekha Multi-Speciality Hospital, Pune, India

and more 7 locations

Respiratory Adaptive Computed Tomography: Feasibility Study on Real-Time Gated 4DCT for Lung Cancer Radiotherapy

Not Applicable

Recruiting

Conditions: Lung Cancer

Interventions: Diagnostic Test: Real-time Gated 4DCT
Diagnostic Test: Conventional 4DCT

First Posted Date: 2021-09-01

Last Posted Date: 2024-06-06

Lead Sponsor: University of Sydney

Target Recruit Count: 30

Registration Number: NCT05030207

Locations: 🇦🇺
Blacktown Hospital, Blacktown, New South Wales, Australia

Better Evidence and Translation for Calciphylaxis

Phase 3

Recruiting

Conditions: Calciphylaxis

Interventions: Drug: Sodium Thiosulfate
Device: Medium Cut-off Dialyser
Device: High Flux Dialyser
Drug: Vitamin K1
Drug: Magnesium citrate
Drug: Placebo capsule (Vitamin K1)
Drug: Placebo injection (normal saline)
Drug: Placebo tablet (Magnesium citrate)

First Posted Date: 2021-08-24

Last Posted Date: 2024-06-21

Lead Sponsor: University of Sydney

Target Recruit Count: 350

Registration Number: NCT05018221

Locations: 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia
🇦🇺
Sunshine Hospital (Western Health), St Albans, Victoria, Australia
🇳🇿
Tauranga Hospital, Tauranga, New Zealand

and more 11 locations

Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema

Not Applicable

Conditions: Macula Edema
Retinal Vein Occlusion

Interventions: Device: Ellex Integre NIR laser

First Posted Date: 2021-04-19

Last Posted Date: 2021-04-19

Lead Sponsor: University of Sydney

Target Recruit Count: 14

Registration Number: NCT04847869

Locations: 🇦🇺
Macular Research Group, Save Sight Institute, The University of Sydney, Sydney, New South Wales, Australia

The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers

Phase 1

Completed

Conditions: SARS-CoV2 COVID-19

Interventions: Biological: COVIGEN C19 2.0 mg IM or Placebo IM
Biological: COVIGEN C20 1.0mg vaccine ID
Biological: COVIGEN C19 0.8 mg ID or Placebo ID
Biological: COVIGEN C19 4.0 mg IM or Placebo IM

First Posted Date: 2021-02-08

Last Posted Date: 2023-10-30

Lead Sponsor: University of Sydney

Target Recruit Count: 68

Registration Number: NCT04742842

Locations: 🇦🇺
Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital, Adelaide, South Australia, Australia
🇦🇺
Scientia Clinical Research, Randwick, New South Wales, Australia
🇦🇺
Wesfarmers Centre of Vaccines and Infectious Diseases Telethon Kids Institute, Perth, Western Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy